Alder Biopharmaceuticals Inc (ALDR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9782
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company which develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel mab xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alder’s clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The company’s eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.

Alder Biopharmaceuticals Inc (ALDR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Alder Biopharma Raises US$38 Million In Series D Financing 11
Licensing Agreements 13
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14
Equity Offering 15
Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18
Alder BioPharma Raises USD230 Million in Public Offering of Shares 20
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22
Alder Biopharma Raises USD88.8 Million in IPO 24
Debt Offering 26
Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26
Alder Biopharmaceuticals Inc – Key Competitors 28
Alder Biopharmaceuticals Inc – Key Employees 29
Alder Biopharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 05, 2018: Alder BioPharmaceuticals reports third quarter 2018 financial and operating results 31
Aug 07, 2018: Alder BioPharmaceuticals reports second quarter 2018 financial and operating results 32
May 08, 2018: Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results 33
Feb 26, 2018: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 34
Nov 07, 2017: Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 36
Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 37
Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 39
Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 41
Corporate Communications 43
Apr 26, 2018: Alder BioPharmaceuticals Appoints Jeremy Green to its Board of Directors 43
Apr 16, 2018: Alder BioPharmaceuticals Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer 44
Mar 20, 2018: Alder BioPharmaceuticals Appoints Paul B. Cleveland as Interim President and Chief Executive Officer 45
Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 46
Product News 47
03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 47
Clinical Trials 48
Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 48
Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 49
Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alder Biopharma Raises US$38 Million In Series D Financing 11
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14
Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18
Alder BioPharma Raises USD230 Million in Public Offering of Shares 20
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22
Alder Biopharma Raises USD88.8 Million in IPO 24
Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26
Alder Biopharmaceuticals Inc, Key Competitors 28
Alder Biopharmaceuticals Inc, Key Employees 29
Alder Biopharmaceuticals Inc, Subsidiaries 30

List of Figures
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Alder Biopharmaceuticals Inc (ALDR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cinkarna Celje d.d. Celje (CICG):企業の財務・戦略的SWOT分析
    Cinkarna Celje d.d. Celje (CICG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • IndigoVision Group plc (IND):企業の財務・戦略的SWOT分析
    Summary IndigoVision Group plc (IndigoVision) is a developer, manufacturer and distributor of end-to-end IP security management systems. The company’s products include management software, cameras and encoders, specialized cameras, body worn video, integration and recorders. Its camera and encoder’s …
  • Penske Automotive Group, Inc.:企業の戦略・SWOT・財務情報
    Penske Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Penske Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Aurora Health Care Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aurora Health Care Inc (AHC) is an integrated, not-for-profit, health care system that provides inpatient and outpatient health care in the State of Wisconsin. The organization offers its healthcare services to communities throughout eastern Wisconsin, northern Illinois and the upper peninsu …
  • Accu-Break Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Accu-Break Pharmaceuticals Inc (Accu-Break) is a developer and provider of pharmaceutical tablet technologies for accurate and customized dosing. The company provides services such as patented technologies, product differentiation, life cycle management, APIs solutions, product enhancement, …
  • Duravit AG:企業の戦略・SWOT・財務情報
    Duravit AG - Strategy, SWOT and Corporate Finance Report Summary Duravit AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Straumann Holding AG (STMN):医療機器:M&Aディール及び事業提携情報
    Summary Straumann Holding AG (Straumann) is a provider of tooth replacement and orthodontic solutions. The company researches, develops, manufactures and markets dental implants, instruments, digital equipment, CADCAM prosthetics, dental biomaterials, software and clear aligners for application in t …
  • State Corporation Bank for Development and Foreign Economic Affairs:電力:M&Aディール及び事業提携情報
    Summary State Corporation Bank for Development and Foreign Economic Affairs (Vnesheconombank) is a bank that offers investment banking and funding services. The company funds and supports investment projects and industrial exports through credits, guarantees and sureties, economic entities authorize …
  • Alliance Healthcare Services Inc (AIQ)-製薬・医療分野:企業M&A・提携分析
    Summary Alliance Healthcare Services Inc (Alliance Healthcare Services) is a provider of outsourced services including diagnostic imaging services. It provides a full line of services ranging from systems, technologists to operate the systems, sales and marketing, patient scheduling and pre-authoriz …
  • Drugs for Neglected Diseases initiative-製薬・医療分野:企業M&A・提携分析
    Summary Drugs for Neglected Diseases initiative (DNDi) is a research center that discovers and develops new drugs. The center develops therapeutics for the treatment of various diseases. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. DNDi also offers products …
  • Aixtron SE (AIXA):企業の財務・戦略的SWOT分析
    Aixtron SE (AIXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Acadia Pharmaceuticals Inc (ACAD)-製薬・医療分野:企業M&A・提携分析
    Summary Acadia Pharmaceuticals Inc (Acadia) discovers, develops and commercializes small molecule drugs for the treatment of central nervous system disorders. The company’s lead product Nuplazid (pimavanserin) is an FDA approved drug for the treatment of Parkinson’s disease psychosis. Acadia also de …
  • Immunogen, Inc.:企業の戦略・SWOT・財務分析
    Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • ENN Energy Holdings Ltd (2688):企業の財務・戦略的SWOT分析
    ENN Energy Holdings Ltd (2688) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Refresco Gerber B.V.:戦略・SWOT・企業財務分析
    Refresco Gerber B.V. - Strategy, SWOT and Corporate Finance Report Summary Refresco Gerber B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ultrapar Participacoes SA (UGPA3):企業の財務・戦略的SWOT分析
    Ultrapar Participacoes SA (UGPA3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Coriolis Telecom SAS:企業の戦略的SWOT分析
    Coriolis Telecom SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Humana Inc (HUM)-医療機器分野:企業M&A・提携分析
    Summary Humana Inc (Humana) is a health and well-being company that offers health insurance and Medicare plans, insurance products, and health and wellness services to healthcare providers, employers, individuals, administrators, government, and the public sector. The company’s Medicare products and …
  • Colorado State University-製薬・医療分野:企業M&A・提携分析
    Summary Colorado State University (CSU) is a public research university that offers various academic programs. It provides graduate degree programs, undergraduate degree programs, research programs, summer programs and honor programs. Its schools and programs include graduate school, international p …
  • Ana Holdings Inc:企業の戦略・SWOT・財務分析
    Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆